In vivo CAR focus Target opportunities around in vivo CAR therapies leveraging Creating Medicines proprietary mRNA-LNP platform to program immune cells directly in the body, addressing oncology, autoimmunity, and fibrosis segments.

Clinical-stage momentum Sales approach should emphasize near-term engagement with clinical-stage programs, particularly MT-302 for TROP2 cancers and first-line gastroesophageal junction carcinoma potential.

Strategic partnerships Position CREATE as a partner for scalable, repeat-dose immunotherapies and next-generation RNA technology to augment biotech and pharma portfolios seeking off-the-shelf immunotherapies.

Financial runway Leverage recent $122M Series B funding and ongoing clinical development to propose collaborative programs, co-development, or licensing that align with pipeline expansion and risk-sharing models.

Advisory strength Engage through high-impact collaborations with newly appointed clinical and scientific advisors to bolster credibility for potential partners and expedite due diligence in collaboration discussions.